Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib [4]

Leukemia

Volumn 19, Issue 12, 2005, Pages 2334-2336

  Cayuela, J M ^a   Rousselot, P ^b,c   Nicolini, F ^d   Espinouse, D ^e   Ollagnier, C ^e   Bui Thi, M H ^a   Chabane, K ^e   Raffoux, E ^b   Callet Bauchu, E ^e,f   Tigaud, I ^e,f   Magaud, J P ^e,f   Hayette, Sandrine ^e,f  

^a Laboratoire Central d'Hematologie   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ADULT; BLOOD ANALYSIS; CANCER PATIENT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FRANCE; FUSION GENE; GENE INSERTION; GENE REARRANGEMENT; GENETIC IDENTIFICATION; GENETIC TRANSCRIPTION; HEALTH CARE FACILITY; HUMAN; INTRON; KARYOTYPE; LETTER; LEUKEMIA REMISSION; LEUKOCYTOSIS; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 28544432559     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2403986     Document Type: Letter

References (9)

1. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukaemia phenotype. Blood 1996; 88: 2375-2384.
2. Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T et al. e8a2 BCR-ABL: More frequent than other atypical BCR-ABL variants? Leukemia 2005; 19: 681-684.
3. Gabert J, Beillard E, van der Veden VHJ, Bi W, Grimwade D, Pallisgaard N et al. Standardisation and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukaemia - A Europe Against Cancer Program. Leukemia 2003; 17: 2318-2357.
4. Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 2000; 109: 635-637.
5. Sugimoto T, Ijima K, Hisatomi H, Murayama T, Mizuno I, Hato A et al. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence. Am J Hematol 2004; 77: 164-166.
6. Martinelli G, Terragna C, Amabile M, Montefusco V, Testoni N, Ottaviani E et al. Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2). Leukemia 1999; 13: 1635-1637.
7. Martinelli G, Terragna C, Amabile M, Montefusco V, Testoni N, Ottaviani E et al. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints. Haematologica 2000; 85: 40-46.
8. Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 2005; 6: 112-126.
9. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321-1331.